Biodexa Pharmaceuticals Valuation

Is BDRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BDRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BDRX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BDRX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BDRX?

Key metric: As BDRX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BDRX. This is calculated by dividing BDRX's market cap by their current revenue.
What is BDRX's PS Ratio?
PS Ratio	26.7x
Sales	UK£83.00k
Market Cap	UK£2.30m

BDRX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BDRX's PS Ratio compare to its peers?

The above table shows the PS ratio for BDRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	11.2x
BIOC Biocept	2x	67.1%	US$2.7m
GRTS.Q Gritstone bio	0.3x	-151.3%	US$3.5m
FRES Fresh2 Group	1x	n/a	US$2.5m
SONN Sonnet BioTherapeutics Holdings	41.5x	n/a	US$2.3m
BDRX Biodexa Pharmaceuticals	26.7x	-70.6%	US$2.9m

Price-To-Sales vs Peers: BDRX is expensive based on its Price-To-Sales Ratio (26.7x) compared to the peer average (14.3x).

Price to Sales Ratio vs Industry

How does BDRX's PS Ratio compare vs other companies in the US Biotechs Industry?

126 Companies	Price / Sales	Estimated Growth	Market Cap
BIIB Biogen	2.4x	1.3%	US$23.13b
MRNA Moderna	3.2x	6.7%	US$16.80b
INCY Incyte	3.5x	9.0%	US$14.16b
ALKS Alkermes	3.1x	-0.7%	US$4.75b

126 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: BDRX is expensive based on its Price-To-Sales Ratio (26.7x) compared to the US Biotechs industry average (9.4x).

Price to Sales Ratio vs Fair Ratio

What is BDRX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BDRX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	26.7x
Fair PS Ratio	0.1x

Price-To-Sales vs Fair Ratio: BDRX is expensive based on its Price-To-Sales Ratio (26.7x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

4.8%

22.3%

IQVIA Holdings

US$37.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.23

5.2%

-4.6%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.86

3.9%

15.0%